Pregabalin

Lyrica (LEER-ih-kah) is the brand name used in the United States and some other countries for the seizure medicine pregabalin (pree-GABA-lin).

Lyrica is similar in structure to one of the major chemical neurotransmitters in the human brain, GABA (gamma aminobutyric acid). GABA is the most important inhibitory neurotransmitter—that is, it prevents nerve cells in the brain from firing too quickly, as they do in seizures. As it turns out, however, Lyrica does not act like GABA in the brain.

Lyrica was approved by the United States Food and Drug Administration (FDA) in 2005.

Lyrica
Tablet
Lyrica 25mg

25-mg (white, hard-gelatin)
Capsules with “Pfizer” on the cap, “PGN 25” on the body

Lyrica 50mg

50-mg (white and with navy stripe, hard-gelatin)
Capsules with “Pfizer” on the cap, “PGN 50” on the body

Lyrica 75mg

75-mg (orange/white, hard-gelatin)
Capsules with “Pfizer” on the cap, “PGN 75” on the body

Lyrica 100mg

100-mg (orange, hard-gelatin)
Capsules with “Pfizer” on the cap, “PGN 100” on the body

Lyrica 150mg

150-mg (white, hard-gelatin)
Capsules with “Pfizer” on the cap, “PGN 150” on the body

Lyrica 200mg

200-mg (light orange, hard-gelatin)
Capsules with “Pfizer” on the cap, “PGN 200” on the body

Lyrica 225mg

225-mg (white/light orange,hard-gelatin)
Capsules with “Pfizer” on the cap, “PGN 225” on the body

Lyrica 300mg

300-mg (white/orange, hard-gelatin)
Capsules with “Pfizer” on the cap, “PGN 300” on the body

Indications

Lyrica is used to treat seizures that begin in a limited area of the brain. These are called partial seizures. Some of them spread throughout the rest of the brain. They are called secondarily generalized seizures. Lyrica does not prevent seizures that begin on both sides of the brain at the same time, called primary generalized seizures.

Lyrica is usually used as an additional seizure medicine when another medicine has not been nable to control all of a person’s partial seizures. This kind of use is called add-on or adjunctive therapy. Lyrica is approved by the U.S. Food and Drug Administration (FDA) as add-on therapy for partial seizures—that is, seizures that begin in a limited area of the brain.

Lyrica may also be effective for some people when used alone (called monotherapy), although the FDA has not approved it to be used in this way.

Forms

Lyrica is sold in the United States by Pfizer Inc. The name or appearance may differ in other places. These descriptions apply to the U.S. versions:

Pregabalin Package insert

In the United States, companies that manufacture medicines are required to publish certain kinds of information about each product. This document is commonly known as a “package insert” because it is usually included with each package of the medicine.

You can also read these documents (also called "prescribing information") online. The U.S. package insert for Lyrica (pregabalin) is found at:

Some of the information may differ in other countries.

To learn how to read and understand a package insert, see How to read a package insert.

Pregabalin References for Professionals

If you visit PubMed, a service of the National Library of Medicine, you can read summaries of studies that have tested Lyrica as well as other reports about this medication.

Here are some of the key published studies of Lyrica for partial seizures, postherpetic neuralgia and painful diabetic neuropathy:

Arroyo S, Anhut H, Kugler AR, et al, and the Pregabalin 1008-011 International Study Group. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia. 2004;45:20-27.

Beydoun A, Uthman BM, Kugler AF, Greiner MJ, Knapp LE, Garofalo EA, and the Pregabalin 1008-009 Study Group. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology. 2005;64:475-480.

Dworkin RH, Corbin AE, Young JP Jr, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003;60:1274-1283.

French JA, Kugler AR, Robbins JL, Knapp LE, Garofalo EA. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology. 2003;60:1631-1637.

Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004;63:2104-2110.

Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004;110:628-638.

Sabatowski R, Gálvez R, Cherry DA, et al, and The 1008-045 Study Group. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain. 2004;109:26-35.

Our Mission

The mission of the Epilepsy Foundation is to lead the fight to overcome the challenges of living with epilepsy and to accelerate therapies to stop seizures, find cures, and save lives.

 
24/7 helpline